• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于生物类似药与原研药之间距离的多变量统计方法进行相似性评估。

Similarity assessment by multivariate statistics method based on the distance between biosimilar and originator.

作者信息

Xu Jian, Shao Zhihui, Han Xiaoxiong, Huang Yingfeng, Zou Xun, Shen Yaling

机构信息

State Key Laboratory of Bioreactor Engineering, Shanghai Collaborative Innovation Center for Biomanufacturing Technology, East China University of Science and Technology, 130 Mei Long Road, Shanghai, 200237, China.

CAS Key Laboratory of Synthetic Biology, CAS Center for Excellence in Molecular Plant Sciences, Institute of Plant Physiology and Ecology, Chinese Academy of Sciences, Shanghai, China.

出版信息

Bioresour Bioprocess. 2021 Mar 29;8(1):24. doi: 10.1186/s40643-021-00378-2.

DOI:10.1186/s40643-021-00378-2
PMID:38650220
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10992075/
Abstract

The development of biosimilar products or follow-on biologics has been flourishing in recent years because of their lower price than the originators. In this study, a multivariate data analysis method based on JMP software was proposed to assess the glycosylation pattern similarity of antibody candidates from different conditions in optimization experiments with a reference. A specific distance was generated by this method and indicated the glycoform similarity between the biosimilar and the reference. This method can be applied to analyze the similarity of other physicochemical and functional characteristics between follow-on biologics and originators. Then, the design of experimental methods can be realized to optimize the conditions of cell culture to attain similar antibody candidates. A higher concentration of GlcNAc added to the basal media made the glycan of the antibody more similar to the glycan of the reference in this study.

摘要

近年来,生物类似药或后续生物制品的开发蓬勃发展,因为它们的价格低于原创药。在本研究中,提出了一种基于JMP软件的多变量数据分析方法,以评估优化实验中不同条件下候选抗体与参考抗体的糖基化模式相似性。该方法生成了一个特定的距离,表明生物类似药与参考抗体之间的糖型相似性。此方法可用于分析后续生物制品与原创药之间其他物理化学和功能特性的相似性。然后,可以实现实验方法的设计,以优化细胞培养条件,获得相似的候选抗体。在本研究中,向基础培养基中添加更高浓度的N-乙酰葡糖胺可使抗体的聚糖更类似于参考抗体的聚糖。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ada8/10992075/f6d116cb33c9/40643_2021_378_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ada8/10992075/4e5340d24c90/40643_2021_378_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ada8/10992075/76c5a0a476ff/40643_2021_378_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ada8/10992075/7e68865edab9/40643_2021_378_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ada8/10992075/f6d116cb33c9/40643_2021_378_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ada8/10992075/4e5340d24c90/40643_2021_378_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ada8/10992075/76c5a0a476ff/40643_2021_378_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ada8/10992075/7e68865edab9/40643_2021_378_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ada8/10992075/f6d116cb33c9/40643_2021_378_Fig4_HTML.jpg

相似文献

1
Similarity assessment by multivariate statistics method based on the distance between biosimilar and originator.基于生物类似药与原研药之间距离的多变量统计方法进行相似性评估。
Bioresour Bioprocess. 2021 Mar 29;8(1):24. doi: 10.1186/s40643-021-00378-2.
2
Developing a medium combination to attain similar glycosylation profile to originator by DoE and cluster analysis method.通过设计实验和聚类分析开发一种中合剂以达到与原研药相似的糖基化模式。
Sci Rep. 2021 Mar 29;11(1):7103. doi: 10.1038/s41598-021-86447-0.
3
Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.英夫利昔单抗和依那西普原研药与相应生物类似药治疗保留率:北欧协作观察性研究 2334 例生物制剂初治的脊柱关节炎患者。
RMD Open. 2019 Oct 23;5(2):e001079. doi: 10.1136/rmdopen-2019-001079. eCollection 2019.
4
Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs.支持生物类似药项目的免疫原性检测方法的开发和验证建议。
AAPS J. 2019 Dec 2;22(1):7. doi: 10.1208/s12248-019-0386-y.
5
Part 1: Physicochemical characterization of bevacizumab in undiluted 25 mg/mL drug product solutions: Comparison of originator with a biosimilar candidate.第一部分:未稀释 25mg/mL 药物产品溶液中贝伐珠单抗的理化特性分析:原研药与生物类似药候选物的比较。
J Pharm Biomed Anal. 2019 Oct 25;175:112742. doi: 10.1016/j.jpba.2019.06.039. Epub 2019 Jul 3.
6
Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.在类风湿关节炎和银屑病试验中,原研 TNF 抑制剂和生物类似药的疗效和安全性结局:系统文献回顾。
BioDrugs. 2018 Jun;32(3):193-199. doi: 10.1007/s40259-018-0283-4.
7
Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs): data from an Italian observational study in nephrology.生物类似药与原研促红细胞生成素(ESA)的风险/获益比较:来自意大利一项肾脏病学观察性研究的数据
Eur J Clin Pharmacol. 2018 Jun;74(6):805-810. doi: 10.1007/s00228-018-2428-2. Epub 2018 Feb 10.
8
Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study.评估生物类似药的结构和功能可比性:以曲妥珠单抗为例。
BioDrugs. 2020 Apr;34(2):209-223. doi: 10.1007/s40259-020-00404-3.
9
Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!识别欧洲非专利生物制品和生物类似药市场的关键优势:不仅仅是价格!
BioDrugs. 2020 Apr;34(2):159-170. doi: 10.1007/s40259-019-00395-w.
10
Hydrophilic Interaction Chromatography Hyphenated with Mass Spectrometry: A Powerful Analytical Tool for the Comparison of Originator and Biosimilar Therapeutic Monoclonal Antibodies at the Middle-up Level of Analysis.亲水作用色谱-质谱联用:一种强大的分析工具,可用于在分析的中程水平上比较原创药和生物类似药治疗性单克隆抗体。
Anal Chem. 2017 Feb 7;89(3):2086-2092. doi: 10.1021/acs.analchem.6b04726. Epub 2017 Jan 25.

引用本文的文献

1
Analytical Similarity Assessment of Biosimilars: Global Regulatory Landscape, Recent Studies and Major Advancements in Orthogonal Platforms.生物类似药的分析相似性评估:全球监管格局、近期研究及正交平台的重大进展
Front Bioeng Biotechnol. 2022 Feb 9;10:832059. doi: 10.3389/fbioe.2022.832059. eCollection 2022.

本文引用的文献

1
The search for biosimilars and biobetters.生物类似药和生物改良药的探索。
Drug Discov Today. 2019 May;24(5):1087-1091. doi: 10.1016/j.drudis.2019.03.016. Epub 2019 Mar 16.
2
Biosimilars: Key regulatory considerations and similarity assessment tools.生物类似药:关键监管考量因素及相似性评估工具
Biotechnol Bioeng. 2017 Dec;114(12):2696-2705. doi: 10.1002/bit.26438. Epub 2017 Sep 19.
3
Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.抗体糖基化及其对单克隆抗体和Fc融合蛋白药代动力学和药效学的影响。
J Pharm Sci. 2015 Jun;104(6):1866-1884. doi: 10.1002/jps.24444. Epub 2015 Apr 14.
4
Statistical assessment of biosimilarity based on relative distance between follow-on biologics.基于后续生物类似药之间相对距离的生物相似性的统计评估。
Stat Med. 2013 Feb 10;32(3):382-92. doi: 10.1002/sim.5582. Epub 2012 Sep 2.
5
Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose.通过投喂尿苷、氯化锰和半乳糖来调节抗体半乳糖基化。
Biotechnol Bioeng. 2011 Jul;108(7):1591-602. doi: 10.1002/bit.23075. Epub 2011 Feb 18.
6
Optimal and consistent protein glycosylation in mammalian cell culture.哺乳动物细胞培养中最佳且一致的蛋白质糖基化
Glycobiology. 2009 Sep;19(9):936-49. doi: 10.1093/glycob/cwp079. Epub 2009 Jun 3.
7
Amino acid and manganese supplementation modulates the glycosylation state of erythropoietin in a CHO culture system.在CHO培养系统中,补充氨基酸和锰可调节促红细胞生成素的糖基化状态。
Biotechnol Bioeng. 2007 Feb 15;96(3):538-49. doi: 10.1002/bit.21141.